ArticleJournal of diabetes investigation2026
Effect of switching from intermittently scanned continuous glucose monitoring to FreeStyle Libre 2 with real-time continuous glucose monitoring and alert functionality.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Technology in Diabetes: A Year in Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS/
introductionThis study aimed to assess the impact of switching from FreeStyle Libre (FSL) to FreeStyle Libre 2 (FSL2) with real-time continuous glucose monitoring (rtCGM) functionality. MATERIALS AND
methodsWe retrospectively assessed 58 patients who transitioned from FSL to FSL2 with rtCGM functionality.
resultsSwitching from FSL to FSL2 significantly increased the valid data acquisition rate (76.8% ± 21.6% vs 90.4% ± 18.0%, P < 0.001). Time in range (TIR) improved from 57.7% ± 18.1% to 61.7% ± 17.1% (P = 0.023); time in tight range improved from 33.3% ± 15.4% to 38.6% ± 16.9% (P = 0.006), and glycated hemoglobin decreased from 7.6% ± 1.1% to 7.4% ± 1.0% (P = 0.009). TIR improvement was immediate in Type 1 diabetes but gradual after an initial decline in Type 2 diabetes. Logistic regression identified younger age as a predictor of TIR improvement (odds ratio: 0.95, 95% confidence interval: 0.90-0.99, P = 0.034).
conclusionsTransitioning from FSL to FSL2 with rtCGM functionality improved valid data acquisition rate and glycemic control, particularly in patients with Type 1 diabetes. The duration required for improvement in continuous glucose monitoring-related parameters varied by diabetes type, with early improvements observed in Type 1 diabetes and gradual improvements in Type 2 diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.